Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:30:02 18/05/2024 am IST			5-day change	1st Jan Change
45.69 ^USD	-0.65%		+4.77%	+2.05%

15/05	Qiagen's Updated Clinical Decision Support Platform Secures EU Certification	MT
14/05	QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret	CI

Qiagen N : 2024 QIAGEN N.V. Annual General Meeting of Shareholders Presentation

May 08, 2024 at 06:06 pm IST

2024 QIAGEN Annual General Meeting

The presentation will be available shortly before the webcast on June 21.

Sample to Insight

Q4 and Full-year 2021 results

Sample to Insight

Q4 and Full-year 2021 results

Attachments

Original Link
Original Document
Permalink

Disclaimer

Qiagen NV published this content on 08 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 May 2024 12:35:01 UTC.

Latest news about Qiagen N.V.

Qiagen's Updated Clinical Decision Support Platform Secures EU Certification	15/05	MT
QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret	15/05	CI
Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test	13/05	MT
Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel	13/05	MT
Qiagen, US FBI to Jointly Develop Digital PCR Assay for Forensics	08/05	MT
QIAGEN Partners with FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics	08/05	CI
QIAGEN Announces the Availability of QCI Secondary Analysis	03/05	CI
QIAGEN NV : Berenberg reaffirms its Buy rating	30/04	ZD
QIAGEN : A decent start to 2024; guidance unchanged	30/04
QIAGEN NV : Deutsche Bank reiterates its Buy rating	30/04	ZD
Qiagen Seeks Acquisitions	30/04	CI
Transcript : Qiagen N.V., Q1 2024 Earnings Call, Apr 30, 2024	30/04
QIAGEN NV : Jefferies remains Neutral	30/04	ZD
QIAGEN NV : UBS remains Neutral	30/04	ZD
QIAGEN NV : UBS remains Neutral	30/04	ZD
QIAGEN NV : UBS sticks Neutral	30/04	ZD
Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours	30/04	MT
Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024	30/04	CI
Qiagen N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use	25/04	CI
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	22/04	MT
QIAGEN NV : Deutsche Bank reiterates its Buy rating	16/04	ZD
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	04/04	CI
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland	27/03	CI
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System	26/03	CI

Chart Qiagen N.V.

Duration

Period

More charts

Company Profile

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Sector

Biotechnology & Medical Research

Calendar

22/05/2024 - Deutsche Bank dbAccess European Champions Conference

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 07:02 pm IST

More Strategies

Ratings for Qiagen N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

45.69 USD

Average target price

50.19 USD

Spread / Average Target

+9.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QIAGEN N.V.	+2.05%	1.01TCr
MODERNA, INC.	+33.63%	5.09TCr
IQVIA HOLDINGS INC.	-0.09%	4.21TCr
LONZA GROUP AG	+49.62%	4.2TCr
CELLTRION, INC.	-4.96%	2.92TCr
ICON PUBLIC LIMITED COMPANY	+11.18%	2.6TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	1.89TCr
BIO-TECHNE CORPORATION	+8.61%	1.32TCr
UNITED THERAPEUTICS CORPORATION	+24.73%	1.22TCr
MEDPACE HOLDINGS, INC.	+28.31%	1.22TCr

Other Biotechnology & Medical Research